NANO: REK godkjenner oppstart av ARCHER

13.06.2018 kl 12:55 6151

Dette er en arkivert tråd!
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway
Oslo, Norway, 13 June 2018

Nordic Nanovector ASA (OSE: NANO) has received approval from the Regional
Committees for Medical and Health Research Ethics (REK) in Norway with regard to
the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with
Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in
second-line follicular lymphoma patients (2L FL).

Nordic Nanovector has now received all necessary approvals to begin Archer-1 in
Norway and will commence start-up activities immediately. Archer-1 is a Phase 1b
clinical trial designed to investigate the safety, tolerability, pharmacokinetic
and preliminary efficacy of the Betalutin®/rituximab combination in approx. 20
2L FL patients, and the study will initially be conducted in Norway. Further
countries are expected to be added later. The first patient is expected to be
dosed in the second half of 2018.